Wells Fargo
RPRX icon

Wells Fargo’s Royalty Pharma RPRX Stock Holding History

Wells Fargo’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.4M Buy
452,671
+88,466
+24% +$4.6M ﹤0.01% 1458
2026
Q1 		$17.5M Buy
364,205
+108,520
+42% +$4.75M ﹤0.01% 1612
2025
Q4 		$9.88M Buy
255,685
+35,422
+16% +$1.35M ﹤0.01% 2054
2025
Q3 		$7.77M Buy
220,263
+144,475
+191% +$5.23M ﹤0.01% 2205
2025
Q2 		$2.73M Sell
75,788
-8,486
-10% -$281K ﹤0.01% 2956
2025
Q1 		$2.62M Buy
84,274
+14,154
+20% +$449K ﹤0.01% 2948
2024
Q4 		$1.79M Buy
70,120
+15,790
+29% +$419K ﹤0.01% 3275
2024
Q3 		$1.54M Buy
54,330
+6,174
+13% +$171K ﹤0.01% 3245
2024
Q2 		$1.27M Sell
48,156
-2,189
-4% -$60.7K ﹤0.01% 3331
2024
Q1 		$1.53M Buy
50,345
+35,453
+238% +$1.05M ﹤0.01% 3175
2023
Q4 		$418K Buy
14,892
+311
+2% +$8.55K ﹤0.01% 3979
2023
Q3 		$396K Sell
14,581
-28,820
-66% -$856K ﹤0.01% 3925
2023
Q2 		$1.33M Buy
43,401
+8,202
+23% +$278K ﹤0.01% 3229
2023
Q1 		$1.27M Buy
35,199
+12,571
+56% +$466K ﹤0.01% 3212
2022
Q4 		$894K Sell
22,628
-16,170
-42% -$675K ﹤0.01% 3310
2022
Q3 		$1.56M Buy
38,798
+3,642
+10% +$156K ﹤0.01% 2917
2022
Q2 		$1.48M Buy
35,156
+7,547
+27% +$309K ﹤0.01% 3024
2022
Q1 		$1.08M Buy
27,609
+3,543
+15% +$139K ﹤0.01% 3827
2021
Q4 		$959K Sell
24,066
-32,848
-58% -$1.28M ﹤0.01% 4146
2021
Q3 		$2.06M Sell
56,914
-49,210
-46% -$1.91M ﹤0.01% 3651
2021
Q2 		$4.35M Buy
106,124
+70,277
+196% +$2.99M ﹤0.01% 2985
2021
Q1 		$1.56M Sell
35,847
-350,796
-91% -$16.6M ﹤0.01% 3914
2020
Q4 		$19.4M Buy
386,643
+357,244
+1,215% +$15.2M ﹤0.01% 1586
2020
Q3 		$1.24M Sell
29,399
-336,931
-92% -$14.5M ﹤0.01% 3687
2020
Q2 		$17.8M Buy
+366,330
New +$18.1M 0.01% 1442

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's RPRX Position: Q2 2026 in Review

Wells Fargo increased its Royalty Pharma (RPRX) stake by 24% in Q2 2026, buying an estimated $4.6M and bringing the position to 452,671 shares worth $25.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Wells Fargo first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Wells Fargo held 452,671 shares of Royalty Pharma worth $25.4M as of Q2 2026.
  • Wells Fargo bought 88,466 Royalty Pharma shares in Q2 2026, an estimated $4.6M.
  • Royalty Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1458 holding.
  • Wells Fargo first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.